Philip Morris CEO on Zyn's Dominance and Smoke-Free Future

Q3 Earnings and Market Performance

• 📊 Despite a beat on Q3 earnings, Philip Morris International shares saw a significant drop, with some analysts expecting more flow-through to guidance.
• 🚀 The company highlighted strong performance across both its US smoke-free products and international markets, indicating robust demand for its smoke-free category.
• 📈 Philip Morris International has achieved 10-11 years of smoke-free transformation, with 42 consecutive quarters of uninterrupted financial and volume growth.

Zyn's Category Growth and Market Share

• 🎯 Zyn has captured approximately 60% of the category growth, a significant increase from its previous 30% share during supply constraints.
• 🗣️ The CEO noted that over 70% of participants in recent promotional schemes were adult smokers and vape users, indicating successful re-engagement.
• ⚠️ While the comeback created some financial pressure, the company is pleased with the consumer reaction and its trajectory.

Macroeconomic Factors and Smoke-Free Strategy

• 🌍 An increasing number of consumers are seeking better alternatives to continued smoking, which is driving Philip Morris International's business growth.
• 💰 Smoke-free products are contributing 70-80% of the company's revenue growth, with demand consistently rising globally.
• 📈 This shift to smoke-free products enhances margins and provides strong returns to investors, evidenced by a recent dividend increase of nearly 9%.

FDA Authorizations and Future Outlook

• 🇺🇸 Philip Morris International is awaiting FDA authorizations for its newest generation of technology for US adult smokers, having retired older versions internationally.
• 🔬 The company believes US adult smokers deserve access to best-in-class technology and is optimistic about FDA's streamlined authorization process.
• 💬 The CEO emphasized the importance of explaining the long-term